Transmissibility and pathogenicity of the severe acute respiratory syndrome coronavirus 2: A systematic review and meta-analysis of secondary attack rate and asymptomatic infection

J Infect Public Health. 2022 Mar;15(3):297-306. doi: 10.1016/j.jiph.2022.01.015. Epub 2022 Jan 31.

Abstract

Background: Understanding the transmissibility and pathogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for control policies, but evidence remains limited.

Methods: We presented a systematic and meta-analytic summary concerning the transmissibility and pathogenicity of COVID-19.

Results: A total of 105 studies were identified, with 35042 infected cases and 897912 close contacts. 48.6% (51/105) of studies on secondary transmissions were from China. We estimated a total SIR of 7.8% (95% confidence interval [CI], 6.8%-8.8%), SAR of 6.6% (95% CI, 5.7%-7.5%), and symptomatic infection ratio of 86.9% (95%CI, 83.9%-89.9%) with a disease series interval of 5.84 (95%CI, 4.92-6.94) days. Household contacts had a higher risk of both symptomatic and asymptomatic infection, and transmission was driven between index cases and second-generation cases, with little transmission occurring in second-to-later-generation cases (SIR, 12.4% vs. 3.6%). The symptomatic infection ratio was not significantly different in terms of infection time, generation, type of contact, and index cases.

Conclusions: Our results suggest a higher risk of infection among household contacts. Transmissibility decreased with generations during the intervention. Pathogenicity of SARS-CoV-2 varied among territories, but didn't change over time. Strict isolation and medical observation measures should be implemented.

Keywords: Asymptomatic infections; COVID-19; Incidence; Meta-analysis; SARS-CoV-2; Virulence.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Asymptomatic Infections / epidemiology
  • COVID-19* / epidemiology
  • Contact Tracing
  • Family Characteristics
  • Humans
  • Incidence
  • SARS-CoV-2*
  • Virulence